USA: Researchers have found in a recent observational study that patients with generalized pustular psoriasis (GPP) face a ...

Mark G. Lebwohl, MD, gives an overview of generalized pustular psoriasis (GPP) and explains how it differs from the more common plaque psoriasis.

But we know with generalized pustular psoriasis [GPP], IL-36 plays a unique role. Talk to us a little bit about what’s different in IL-36 and why is it uniquely positioned for GPP patients.

AAD > Psoriasis. IL-36 And Generalized Pustular Psoriasis: L'chaim! – An American Academy of Dermatology Reading Room selection March 25, 2022 Warren R. Heymann, MD, FAAD ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

Of the 53 patients in the initial treatment group, 61.8% achieved a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) pustulation subscore of 0 at week 1, while 84.4% did so at ...

LEO is claiming global commercial rights to Spevigo for GPP, but will also collaborate with Boehringer on potential follow-up ...

Three-quarters of patients with generalized pustular psoriasis demonstrated response to treatment with an interleukin-36-targeted therapy as early as 4 weeks, according to a study.“Generalized ...

The Food and Drug Administration (FDA) has approved Spevigo ® (spesolimab-sbzo) for the treatment of generalized pustular psoriasis flares in adults.. Spevigo is a humanized monoclonal ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.